ReviewTranslational psychiatry2025
Found in translation: orexin receptor antagonism for the treatment of opioid use disorder.
Review in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hypothalamic Glutamatergic/Orexinergic Neurons Attenuate Fentanyl-Induced Respiratory Depression via Medullary Pre-BöTzinger Complex Pathways.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Can the incentive-sensitization theory of addiction incorporate addiction to opioid drugs?Psychopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Existing pharmacological treatment options for opioid use disorder (OUD) face challenges that limit their efficacy. Accumulating preclinical evidence implicates the orexin/hypocretin system in numerous aspects of OUD development and symptomology: opioid use, opioid-associated cue-driven drug seeking, and opioid withdrawal states that lead to relapse. Further, these studies indicate that selective and dual orexin receptor antagonists (SORAs and DORAs) could constitute promising treatments for OUD and other substance use disorders. Several DORAs have already been approved by the FDA for the treatment of insomnia, making their prospective repurposing potentially straightforward. To this end, recent clinical trials have demonstrated multifaceted efficacy of DORAs for ameliorating opioid craving, withdrawal, and related sleep disturbances in individuals with OUD. Consequently, warranted calls are mounting for the broader use of these agents in the treatment of OUD. This review adopts a translational approach to achieve several aims: (1) to outline the fundamental theories of orexin system function and relate orexinergic dysfunction to the disordered motivation and withdrawal states that characterize OUD; (2) to provide an up-to-date evaluation of preclinical and clinical evidence bases supporting the efficacy of orexin receptor antagonism for the treatment of OUD; (3) to discuss key clinical considerations of repurposing DORAs for OUD treatment, including safety and side effects (i.e., respiratory depression, anhedonia, and risk for abuse); and (4) to highlight the ongoing clinical efforts to determine therapeutic efficacy and safety profiles of DORAs for use in OUD populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.